Notice2024-26661
Government Owned Inventions Available for Licensing or Collaboration: Improved Methods for Cryopreservation of Cells, Tissues, and Organs
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 15, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Eye Institute (NEI), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of licensing and/or collaboration opportunities for the inventions listed below, which are owned by an agency of the U.S. Government and are available for licensing and/or collaboration to achieve expeditious commercialization of results of federally-funded research and development.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 221 (Friday, November 15, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 221 (Friday, November 15, 2024)]
[Notices]
[Pages 90300-90301]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-26661]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions Available for Licensing or
Collaboration: Improved Methods for Cryopreservation of Cells, Tissues,
and Organs
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Eye Institute (NEI), an institute of the National
Institutes of Health (NIH), Department of Health and Human Services
(HHS), is giving notice of licensing and/or collaboration opportunities
for the inventions listed below, which are owned by an agency of the
U.S. Government and are available for licensing and/or collaboration to
achieve expeditious commercialization of results of federally-funded
research and development.
FOR FURTHER INFORMATION CONTACT: Inquiries related to these licensing
and/or collaboration opportunities should be directed to: Hiba
Alsaffar, Ph.D., Technology Transfer Manager, NCI, Technology Transfer
Center, Email: <a href="/cdn-cgi/l/email-protection#127a7b70733c737e617374747360527c7b7a3c757d64"><span class="__cf_email__" data-cfemail="2e46474c4f004f425d4f48484f5c6e40474600494158">[email protected]</span></a> or Phone: 240-276-7489.
SUPPLEMENTARY INFORMATION: Researchers at the NEI seek licensing and/or
co-development research collaborations for improved methods of
cryopreservation of cells, tissues, and organs via FOXO1 activation.
The cornea is a critical part of the eye that helps prevent debris from
entering and refracts light for proper vision. Corneal disorders such
as keratoconus, Fuchs dystrophy, and infectious keratitis require
corneal transplantation to restore vision. Approximately 185,000
corneal transplants are performed annually worldwide to treat corneal
disorders. Corneas for those transplants are supplied by donor eyes
that are stored at eye banks in select countries. Currently, Optisol-
GS<SUP>TM</SUP> is the corneal preservation solution that is most
widely used to store donated corneas at eye banks. Per NEI guidelines,
corneas preserved in Optisol-GS<SUP>TM</SUP> have a 12-day shelf life.
With the high demand for corneal transplantations worldwide, a 12-day
shelf life cannot meet the requirement for long term cryogenic storage
of corneas at large eye banks. Scientists at the NEI have developed
improved methods for cryopreservation of cells, tissues, and organs
(with focus of corneal tissue/cells) that increases
[[Page 90301]]
cold storage shelf life 2.5 times longer than current market products.
This Notice is in accordance with 35 U.S.C. 209 and 37 CFR part
404.
NIH Reference Number: E-013-2021.
Related Technologies: E-073-2018.
Product Type: Medical/Research Tool.
Therapeutic Area(s): Eye, Ear, Nose or Throat.
Potential Commercial Applications:
<bullet> Corneal biobanks.
<bullet> Transplantation to remedy a wide range of corneal
disorders.
<bullet> Improved method of cryopreserving corneal cells and other
cell types.
Competitive Advantages:
<bullet> Superior corneal shelf life: 16-day compared to 12-day
maximum shelf-life of current market products.
<bullet> Better meets requirement for larger eye bank
cryopreservation.
<bullet> 95% endothelial cell survival after 4 weeks in cold
storage.
Patent Status: National Stage Filings in the US, CA, AU, CN, EP.
Development Stage: Discovery.
Dated: November 12, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2024-26661 Filed 11-14-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 15, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.